	US 12,133,840 B2
	Halogenated xanthene composition and method for treating hematologic cancers
Eric A. Wachter, Oak Ridge, TN (US); Dominic Rodrigues, Knoxville, TN (US); Satbir Thakur, Calgary (CA); Lucy Swift, Calgary (CA); Chunfen Zhang, Calgary (CA); Mohit Jain, Calgary (CA); and Aru Narendran, Calgary (CA)
Assigned to Provectus Pharmatech, Inc., Knoxville, TN (US); and UTI Limited Partnership, Calgary (CA)
Filed by Provectus Pharmatech, Inc., Knoxville, TN (US); and UTI Limited Partnership, Calgary (CA)
Filed on Aug. 18, 2022, as Appl. No. 17/890,659.
Application 17/890,659 is a division of application No. 16/688,319, filed on Nov. 19, 2019, granted, now 11,419,844.
Prior Publication US 2024/0082206 A1, Mar. 14, 2024
Int. Cl. A61K 31/352 (2006.01); A61K 9/00 (2006.01); A61K 31/21 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01)

CPC A61K 31/352 (2013.01) [A61K 9/0019 (2013.01); A61K 31/21 (2013.01); A61P 35/00 (2018.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01); C07K 16/2875 (2013.01)]

15 Claims

1. A method of treating a mammalian subject having multiple myeloma comprising the steps of:

(A) administering a therapeutically effective amount of a halogenated xanthene, a pharmaceutically acceptable salt or a C₁-C₄alkyl ester thereof as a first cancer cytotoxic agent dissolved or dispersed in a pharmaceutically acceptable aqueous medium to a mammalian subject having multiple myeloma; and

(B) maintaining said mammalian subject for a period of time sufficient to induce death of said multiple myeloma cells,

wherein said first cancer cytotoxic agent halogenated xanthene, pharmaceutically acceptable salt or C₁-C₄alkyl ester thereof is rose bengal disodium salt.